The cytotoxicity evaluation of magnetic iron oxide nanoparticles on human aortic endothelial cells
- Gaoyuan Ge†1, 2,
- Hengfang Wu†2,
- Fei Xiong3,
- Yu Zhang3,
- Zhirui Guo4,
- Zhiping Bian1,
- Jindan Xu2,
- Chunrong Gu1,
- Ning Gu3,
- Xiangjian Chen1Email author and
- Di Yang2Email author
© Ge et al.; licensee Springer. 2013
Received: 14 March 2013
Accepted: 20 April 2013
Published: 7 May 2013
One major obstacle for successful application of nanoparticles in medicine is its potential nanotoxicity on the environment and human health. In this study, we evaluated the cytotoxicity effect of dimercaptosuccinic acid-coated iron oxide (DMSA-Fe2O3) using cultured human aortic endothelial cells (HAECs). Our results showed that DMSA-Fe2O3 in the culture medium could be absorbed into HAECs, and dispersed in the cytoplasm. The cytotoxicity effect of DMSA-Fe2O3 on HAECs was dose-dependent, and the concentrations no more than 0.02 mg/ml had little toxic effect which were revealed by tetrazolium dye assay. Meanwhile, the cell injury biomarker, lactate dehydrogenase, was not significantly higher than that from control cells (without DMSA-Fe2O3). However, the endocrine function for endothelin-1 and prostacyclin I-2, as well as the urea transporter function, was altered even without obvious evidence of cell injury in this context. We also showed by real-time PCR analysis that DMSA-Fe2O3 exposure resulted in differential effects on the expressions of pro- and anti-apoptosis genes of HAECs. Meanwhile, it was noted that DMSA-Fe2O3 exposure could activate the expression of genes related to oxidative stress and adhesion molecules, which suggested that inflammatory response might be evoked. Moreover, we demonstrated by in vitro endothelial tube formation that even a small amount of DMSA-Fe2O3 (0.01 and 0.02 mg/ml) could inhibit angiogenesis by the HAECs. Altogether, these results indicate that DMSA-Fe2O3 have some cytotoxicity that may cause side effects on normal endothelial cells.
KeywordsMagnetic nanoparticles Iron oxide Endothelial cells Cell viability Angiogenesis
The application of magnetic nanoparticles (MNPs) in diagnosis and effective treatment of diseases has become an area of increasing interest in the biomedical sciences [1–4]. Drug delivery is used to carry drugs region-specifically by attaching them to MNPs and releasing the drug in vivo to the target locale [5–9]. Via AC magnetic fields, the MNPs can mediate hyperthermia for in situ cancer-targeted therapy and be used for in vitro cancer cell-targeted detecting systems [10–14]. Similarly, cells of interest labeling with large amounts of MNPs can be located, tracked, and recovered by imaging techniques such as high-resolution magnetic resonance imaging [15–18].
MNPs of iron oxide (Fe3O4, γ-Fe2O3) may develop to be the modest and biocompatible one with the rapid progress in biological applications research [19, 20]. Many investigations have studied the use of diverse organic coatings as a way of optimizing the delivery of MNPs to or into cell. Several studies have confirmed that a simple dimercaptosuccinic acid (DMSA) coating can enhance the rate of uptake by three orders of magnitude, presumptively by engendering the MNPs with an anionic charge, leading to nonspecific adsorption to the cell surface followed by endocytosis into the cell [21–23]. These methods can deliver huge amounts of MNPs into the cells, but a proven concern arises over the impacts that great intracellular concentrations of MNPs might have on normal cell behavior. A quantitative model cell system indicates that intracellular delivery of even restrained levels of iron oxide (Fe2O3) nanoparticles may affect cell function. To be more specific, the cytotoxicity investigations show that exposure to mounting concentrations of anionic MNPs, from 0.15 to 15 mM of iron, results in a dose-dependent decreasing viability and capacity of PC12 cells to spread neurites in return for nerve growth factor .
In addition to drug delivery, many biomedical applications of MNPs such as magnetic tracking and hyperthermia need a very great deal of MNPs to be injected into blood vessels, which are lined by endothelial cells (ECs), a single squamous epithelial cell layer and an anticoagulant barrier between the vessel wall and blood. EC is involved in the immune and inflammatory response, coagulation, growth regulation, production of extracellular matrix components, and is a modulator of blood flow and blood vessel tone. EC injury, activation, or dysfunction is a hallmark of many pathologic states including atherosclerosis, loss of semi-permeable membrane function, and thrombosis . A wide variety of stimuli can induce programmed cell death (apoptosis) of endothelial cells through extrinsic (death receptor) and/or intrinsic (mitochondria) apoptotic pathway, which is ultimately executed by the intracellular proteases called caspases. There also exist caspase-independent pathways of apoptosis and anti-apoptotic proteins, which can protect cells from apoptosis. These pathways and proteins compose the complicated network of the cell apoptosis [26–29]. When injecting MNPs into blood vessels, ECs is the first tissue barrier encountered by the MNPs. The focus of this study is thus on the cytotoxicity evaluation of DMSA-coated Fe2O3 nanoparticles (DMSA-Fe2O3) on human aortic endothelial cell (HAEC), which is able to proliferate for many generations maintaining its endothelial characteristic and is widely used for in vitro study .
Dulbecco's modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were purchased from GIBCO Company (Grand Island, New York, USA). Endothelial cell growth supplement (ECGS) was supplied by M&C Gene Technology (Beijing, China). MEM non-essential amino acid solution (100×), l-glutamine, thiazolyl blue tetrazolium bromide, haematoxylin, penicillin, and streptomycin were obtained from Sigma-Aldrich (St Louis, MO, USA). Prostacyclin I-2 (PGI-2), endothelin-1 (ET-1), and nitric oxide (NO) assay kits were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Primers were synthesized by Sangon Biotechnology Co., Ltd. (Shanghai, China), and RNAiso Plus reagent, PrimeScript™ RT reagent Kit, and SYBR Premix Ex Taq™ were from TaKaRa Biotechnology Co., Ltd. (Dalian, China). Matrigel basement membrane matrix was from Becton Dickinson (Bedford, MA, USA).
Preparation of DMSA-Fe2O3 nanoparticles
The DMSA-Fe2O3 was prepared by co-authors Dr. Fei Xiong, Dr. Yu Zhang, and Dr. Ning Gu. The characterization data, such as transmission electronic microscopy (TEM) images, crystal structure, surface charge, and magnetic measurements and Fourier transform infrared spectroscopy measurements were determined as the previous report in Dr. Gu's Lab . In the present study, quasi-spherical DMSA-Fe2O3 with an average diameter of 10 nm, was diluted in deionized water to 1 mg/ml, and then further diluted in tested concentrations with cell culture medium before using.
HAECs were used for experiments at passages 2 to 5. HAECs were cultured in DMEM supplemented with 1% ECGS, 20% FBS, 1% heparin sodium, 1% non-essential amino acid solution (100×), 1% l-glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin. Cells were maintained at 37°C in a humidified incubator with 5% CO2.
Location of DMSA-Fe2O3 in the HAEC
For TEM analysis, the HAECs incubated with 0.02 mg/ml DMSA-Fe2O3 for 24 h were washed with PBS and routinely fixed, dehydrated, and embedded . Ultrathin sections (80 nm) were transferred to the 200 mesh copper grid, stained with 5% lead tetraacetate, air-dried, and then examined with a TEM (JEM-1010, JEOL, Akishima-shi, Japan) at 80 kV.
Cell viability/cytotoxicity assay
The cytotoxicity of DMSA-Fe2O3 against HAECs was investigated by the tetrazolium dye (MTT) assay . For the dose-dependent effect, the DMSA-Fe2O3, diluted with culture medium at graded concentrations from 0.001 to 0.2 mg/ml, was applied to the HAECs for 24 h. For the time-dependent effect, 0.05 mg/ml of DMSA-Fe2O3 was applied to the cells for 4, 24, 48, and 72 h, respectively. After washing with PBS, the cells were incubated with MTT solution at 37°C for 2 h, and the dyes were dissolved by dimethyl sulfoxide (DMSO) for 15 min. Absorbance was examined at 595 nm with the Ultra Microplate Reader ELX808IU, and cell viability was calculated as a percentage of control cells treated without DMSA-Fe2O3. Each experiment was repeated at least three times independently.
Assessments of HAEC injury markers and endocrine factors
In this study, HAECs were co-cultured with 0.02 mg/ml of DMSA-Fe2O3 for 24 h. Then, the cell culture supernatant was centrifuged at 8000 × g, 4°C for 30 min to remove the rest of the nanoparticles and cell debris. ET-1, PGI-2, and NO concentrations in the supernatant were measured using ELISA kits according to the manufacturer's instructions, respectively. Lactate dehydrogenase (LDH) and urea were determined using an automatic biochemistry analyzer (Olympus AU5400, Olympus Corporation, Shinjuku-ku, Japan).
Real-time PCR analysis of HAEC gene expression
Thirty-eight genes related to apoptosis cascade, endoplasmic reticulum (ER) stress, oxidative stress, adhesion molecules, and calcium-handling proteins were detected by real-time PCR. In this study, HAECs were incubated with 0.02 mg/ml of DMSA-Fe2O3 for 24 h. The total RNA (300 ng) extracted from HAECs was reverse-transcribed using the PrimeScript™ RT reagent Kit, and then the cDNA was amplified using the SYBR Premix Ex Taq™ according to the following cycle conditions: 30 s at 95°C for 1 cycle, 5 s at 95°C, and 30 s at 60°C for 40 cycles (AB 7900HT Fast Real-Time PCR system). All real-time PCR reactions were performed in triplicate. The housekeeping gene GAPDH was used as an internal control. The fold changes of target gene expression relative to those of the control group were analyzed by the 2-ΔΔCT method , divided into different ranges and depicted as different colors.
Effects of DMSA-Fe2O3 on HAEC tube formation
The tube formation assay is one of the most widely used assays to model the reorganization stage of angiogenesis in vitro. The assay measures the ability of endothelial cells, plated at subconfluent densities with the appropriate extracellular matrix support, to form capillary-like structures. In this study, the Matrigel basement membrane matrix was used as extracellular matrix support to observe whether angiogenesis of HAEC can be intervened by DMSA-Fe2O3 or not. For HAEC tube formation, 50 μl/well of the Matrigel basement membrane matrix was added to a 96-well plate and allowed to gel for 60 min at 37°C. Then, HAECs were seeded at a density of 1.5 × 104 cells/well on the surface of the gel in the presence or absence of conditioned DMSA-Fe2O3 and incubated for 14 h at 37°C in a CO2 incubator. Meanwhile, the high urea solution (6M urea) was used as a positive control for inhibition of tube formation. The cultures on the gel were fixed for 10 min in 25% glutaraldehyde, washed, and stained with Mayer’s hematoxylin. Each well was inspected under a light microscope at ×100 magnification and captured more than three pictures from different fields. Image-Pro plus (IPP) 6.0 for Windows software (Media Cybernetics, Inc., Rockville, MD, USA) was used to measure the length of tube formation on each picture. The average data from the same well was calculated as its quantitative value.
The data were represented as mean ± SD of no less than three independent experiments. Statistical analysis was performed using a student's t test. A value of p < 0.05 was considered statistically significant.
Results and discussion
Endocytosis of DMSA-Fe2O3 by HAECs
HAECs viability studies
The tetrazolium dye (MTT) assay has been used for detecting the number of viable cells (proliferation) and loss of viable cells (cytotoxicity) resulting from toxic materials since only living cells can reduce the MTT to its insoluble form, formazan, which can be quantitatively measured after dissolved in DMSO by a spectrophotometer, and the resultant value is linked to the number of living cells .
To study the time-dependent effect of DMSA-Fe2O3 on HAECs viability, cells were incubated with 0.05 mg/ml of DMSA-Fe2O3 for 4, 24, 48, and 72 h, respectively (Figure 2b). Decreased cell viability occurred as early as 4 h and varied in a range from 75.8% to 93.1% to the control group at tested time points. The results suggest that the cytotoxic effect of DMSA-Fe2O3 on HAECs is dose-dependent, and the concentrations no more than 0.02 mg/ml are relatively harmless in the present study.
Effects of DMSA-Fe2O3 on HAEC injury markers and endocrine factors
We then examined whether the endocrine function of HAECs was changed when exposed to this low dose of DMSA-Fe2O3 that did not cause measurable cell injury. ECs can regulate blood pressure and blood flow by releasing vasodilators such as NO and PGI-2, as well as vasoconstrictors, including ET-1. So, the endocrine function of cultured HAECs can be assessed by detecting the above-mentioned factors in the supernatant. We found that the release of NO was not changed in the HAECs treated with 0.02 mg/ml DMSA-Fe2O3 for 24 h (Figure 3). NO released toward the vascular lumen is the most important stimulator for vascular dilator and a potent inhibitor of platelet aggregation and adhesion. NO protects against the onset and later steps in atherogenesis, and thus is one of the most important protective molecules in the vasculature. Endothelial NO synthase (eNOS) is the predominant NOS isoform in the vasculature responsible for most of the vascular NO production. A functional eNOS oxidizes its substrate l-arginine to l-citrulline and NO. Our results indicate that the eNOS function in the HAECs is not affected by treatment with 0.02 mg/ml DMSA-Fe2O3 for 24 h.
In contrast to the release of NO, the release of another vasodilator PGI-2 and the vasoconstrictor ET-1 was significantly decreased in the HAECs treated with 0.02 mg/ml DMSA-Fe2O3 for 24 h (Figure 3, p < 0.01 vs. control group). Besides its function as an effective vasodilator, PGI-2 can prevent platelet plug formation by inhibiting platelet activation. PGI-2 is produced in endothelial cells from prostaglandin H2 by the action of the enzyme PGI-2 synthase. ET-1 is secreted constitutively by endothelial cells from its inactive intermediate, big ET-1, through the action of endothelin-converting enzyme, which is present at the EC surface and on intracellular vesicles. Expression and release of PGI-2 and ET-1 in the ECs are regulated by complex signals; we did not study the mechanism for their reducing expressions and/or release in this study. However, our results demonstrate that the endocrine functions of HAECs are sensitive to DMSA-Fe2O3 treatment, and these functions may be interfered before severe cell injuries occur.
In addition to the cellular-releasing function of these vessel tone regulators, we also studied the cellular uptake function by examining the urea transporter function. The transporter for urea is expressed in the vascular endothelium that transports urea into the cell. Urea plays a significant role in the endothelial cell, and previous studies have revealed that uremic levels of urea (25 mM) inhibit l-arginine transport in cultured endothelial cells . In this study, we found that the urea concentration in the HAECs treated with 0.02 mg/ml of DMSA-Fe2O3 for 24 h was significantly higher than that in control cells (Figure 3, p < 0.05). This observation suggests that the function of urea transporter in the HAECs is also inhibited by the DMSA-Fe2O3 exposure.
Gene expression on HAECs
In this study, the expressions of all four tested genes involved in ER stress, were down-regulated in DMSA-Fe2O3-treated HAECs (Figure 4), especially the AFT4 gene (activating transcription factor 4), whose expression was decreased by over 50%. In contrast, most of the examined genes related to oxidative stress showed an increased change in DMSA-Fe2O3-treated HAECs with the expression of SOD2 (superoxide dismutase 2) and PTGS2 (cyclooxygenase-2, COX-2) elevated to 1.96- and 2.44-fold, respectively. COX-2 is unexpressed under the normal conditions but elevated during an inflammation. The data suggest that oxidative stress, not ER stress, is sensitive to DMSA-Fe2O3. In addition, the expression of NOS3 (eNOS) was mildly decreased in DMSA-Fe2O3-treated HAECs, which was consistent to the result of NO concentration (Figure 3).
We found up-regulation of gene expression for cell-cell contact and adhesion including ICAM1 (intercellular adhesion molecule 1, ICAM-1), VCAM1 (vascular cell adhesion protein 1, VCAM-1), and SELE (endothelial-leukocyte adhesion molecule 1, E-selectin) (3.3-, 4.9-, and 8.1-fold, respectively, Figure 4). ICAM-1 is a type of intercellular adhesion molecule which continuously presents in low concentrations in the membranes of leukocytes and endothelial cells, and greatly increases upon cytokine stimulation. VCAM-1 and E-selectin are cell adhesion molecules expressed only after the endothelial cells being stimulated by cytokines and thus play an important role in inflammation. Thus, together with the data from genes associated with oxidative stress, the results of adhesion molecular genes indicate that inflammation response is likely evoked in HAECs following 0.02 mg/ml DMSA-Fe2O3 treatment before the onset of cell death.
Effects of DMSA-Fe2O3 on HAECs tube formation
In summary, the present study shows that DMSA-Fe2O3 nanoparticles absorbed by the HAECs can cause a dose-dependent cytotoxic event. HAECs exposed to even a small amount of DMSA-Fe2O3 may have impaired endocrine function and angiogenic functions without obvious cell toxicity. Furthermore, the genes related to oxidative stress and inflammation response were activated. Therefore, cautious evaluation of DMSA-Fe2O3 nanoparticles in vivo is needed before applying them in medicine.
This work was supported by the National Natural Science Foundation of China (nos. 81170220 and 81100156), Jiangsu Province Health Foundation (RC2011075), and the Open Project by Jiangsu Key Laboratory for Biomaterials and Devices. We would like to thank Dr. Bin Zhou (Department of Genetics, Albert Einstein College of Medicine of Yeshiva University, New York, USA) for the critical reading, advice, and comments of the manuscript.
- Sjogren CE, Johansson C, Naevestad A, Sontum PC, Briley-Saebo K, Fahlvik AK: Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. Magn Reson Imaging 1997, 15: 55–67. 10.1016/S0730-725X(96)00335-9View ArticleGoogle Scholar
- Halbreich A, Roger J, Pons JN, Geldwerth D, Da Silva MF, Roudier M, Bacri JC: Biomedical applications of maghemite ferrofluid. Biochimie 1998, 80: 379–390. 10.1016/S0300-9084(00)80006-1View ArticleGoogle Scholar
- Perez JM, O'Loughin T, Simeone FJ, Weissleder R, Josephson L: DNA-based magnetic nanoparticle assembly acts as a magnetic relaxation nanoswitch allowing screening of DNA-cleaving agents. J Am Chem Soc 2002, 124: 2856–2857. 10.1021/ja017773nView ArticleGoogle Scholar
- Dyal A, Loos K, Noto M, Chang SW, Spagnoli C, Shafi KV, Ulman A, Cowman M, Gross RA: Activity of Candida rugosa lipase immobilized on gamma-Fe2O3 magnetic nanoparticles. J Am Chem Soc 2003, 125: 1684–1685. 10.1021/ja021223nView ArticleGoogle Scholar
- Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS: Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000, 60: 6641–6648.Google Scholar
- Vasir JK, Labhasetwar V: Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005, 4: 363–374.View ArticleGoogle Scholar
- Zhang R, Wang X, Wu C, Song M, Li J, Lv G, Zhou J, Chen C, Dai Y, Gao F, Fu D, Li X, Guan Z, Chen B: Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology 2006, 17: 3622–3626. 10.1088/0957-4484/17/14/043View ArticleGoogle Scholar
- Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J: Magnetic nanoparticles for drug delivery. Nano Today 2007, 2: 22–32.View ArticleGoogle Scholar
- Dandamudi S, Campbell RB: The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 2007, 28: 4673–4683. 10.1016/j.biomaterials.2007.07.024View ArticleGoogle Scholar
- Jordan A, Scholz R, Maier-Hauff K, van Landeghem FK, Waldoefner N, Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B, von Deimling A, Felix R: The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2006, 78: 7–14. 10.1007/s11060-005-9059-zView ArticleGoogle Scholar
- Ito A, Shinkai M, Honda H, Kobayashi T: Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther 2001, 8: 649–654. 10.1038/sj.cgt.7700357View ArticleGoogle Scholar
- Moroz P, Jones SK, Gray BN: Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 2002, 18: 267–284. 10.1080/02656730110108785View ArticleGoogle Scholar
- Kawashita M, Tanaka M, Kokubo T, Inoue Y, Yao T, Hamada S, Shinjo T: Preparation of ferrimagnetic magnetite microspheres for in situ hyperthermic treatment of cancer. Biomaterials 2005, 26: 2231–2238. 10.1016/j.biomaterials.2004.07.014View ArticleGoogle Scholar
- Chen L, Bao CC, Yang H, Li D, Lei C, Wang T, Hu HY, He M, Zhou Y, Cui DX: A prototype of giant magnetoimpedance-based biosensing system for targeted detection of gastric cancer cells. Biosens Bioelectron 2011, 26: 3246–3253. 10.1016/j.bios.2010.12.034View ArticleGoogle Scholar
- Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R: Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000, 18: 410–414. 10.1038/74464View ArticleGoogle Scholar
- Kircher MF, Rhea JT, Kihiczak D, Novelline RA: Frequency, sensitivity, and specificity of individual signs of diverticulitis on thin-section helical CT with colonic contrast material: experience with 312 cases. AJR Am J Roentgenol 2002, 178: 1313–1318. 10.2214/ajr.178.6.1781313View ArticleGoogle Scholar
- Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, Bhattarai N, Ellenbogen R, Sze R, Hallahan A, Olson J, Zhang M: Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005, 5: 1003–1008. 10.1021/nl0502569View ArticleGoogle Scholar
- Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J: Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 2005, 127: 5732–5733. 10.1021/ja0422155View ArticleGoogle Scholar
- Gojova A, Guo B, Kota RS, Rutledge JC, Kennedy IM, Barakat AI: Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ Health Perspect 2007, 115: 403–409. 10.1289/ehp.115-a403View ArticleGoogle Scholar
- Muller K, Skepper JN, Posfai M, Trivedi R, Howarth S, Corot C, Lancelot E, Thompson PW, Brown AP, Gillard JH: Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials 2007, 28: 1629–1642. 10.1016/j.biomaterials.2006.12.003View ArticleGoogle Scholar
- Wilhelm C, Gazeau F, Bacri JC: Magnetophoresis and ferromagnetic resonance of magnetically labeled cells. Eur Biophys J 2002, 31: 118–125. 10.1007/s00249-001-0200-4View ArticleGoogle Scholar
- Billotey C, Wilhelm C, Devaud M, Bacri JC, Bittoun J, Gazeau F: Cell internalization of anionic maghemite nanoparticles: quantitative effect on magnetic resonance imaging. Magn Reson Med 2003, 49: 646–654. 10.1002/mrm.10418View ArticleGoogle Scholar
- Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F: Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003, 24: 1001–1011. 10.1016/S0142-9612(02)00440-4View ArticleGoogle Scholar
- Pisanic TR 2nd, Blackwell JD, Shubayev VI, Finones RR, Jin S: Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007, 28: 2572–2581. 10.1016/j.biomaterials.2007.01.043View ArticleGoogle Scholar
- Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Schmidt AM, Stern DM: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91: 3527–3561.Google Scholar
- Pober JS, Min W, Bradley JR: Mechanisms of endothelial dysfunction, injury, and death. Annu Rev Pathol 2009, 4: 71–95. 10.1146/annurev.pathol.4.110807.092155View ArticleGoogle Scholar
- Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D: Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004, 94: 370–376. 10.1161/01.RES.0000113782.07824.BEView ArticleGoogle Scholar
- Winn RK, Harlan JM: The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 2005, 3: 1815–1824. 10.1111/j.1538-7836.2005.01378.xView ArticleGoogle Scholar
- Gu X, Yao Y, Cheng R, Zhang Y, Dai Z, Wan G, Yang Z, Cai W, Gao G, Yang X: Plasminogen K5 activates mitochondrial apoptosis pathway in endothelial cells by regulating Bak and Bcl-x(L) subcellular distribution. Apoptosis 2011, 16: 846–855. 10.1007/s10495-011-0618-9View ArticleGoogle Scholar
- Donnini D, Perrella G, Stel G, Ambesi-Impiombato FS, Curcio F: A new model of human aortic endothelial cells in vitro. Biochimie 2000, 82: 1107–1114. 10.1016/S0300-9084(00)01195-0View ArticleGoogle Scholar
- Zhang S, Chen X, Gu C, Zhang Y, Xu J, Bian Z, Yang D, Gu N: The effect of iron oxide magnetic nanoparticles on smooth muscle cells. Nanoscale Res Lett 2008, 4: 70–77.View ArticleGoogle Scholar
- Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P: Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem 2005, 16: 1181–1188. 10.1021/bc050050zView ArticleGoogle Scholar
- Gupta AK, Berry C, Gupta M, Curtis A: Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis. IEEE Trans Nanobioscience 2003, 2: 255–261. 10.1109/TNB.2003.820279View ArticleGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25: 402–408. 10.1006/meth.2001.1262View ArticleGoogle Scholar
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65: 55–63. 10.1016/0022-1759(83)90303-4View ArticleGoogle Scholar
- Chopra J, Joist JH, Webster RO: Loss of 51chromium, lactate dehydrogenase, and 111indium as indicators of endothelial cell injury. Lab Invest 1987, 57: 578–584.Google Scholar
- Xiao S, Wagner L, Mahaney J, Baylis C: Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol 2001, 280: F989-F995.Google Scholar
- Lee YW, Kuhn H, Hennig B, Toborek M: IL-4 induces apoptosis of endothelial cells through the caspase-3-dependent pathway. FEBS Lett 2000, 485: 122–126. 10.1016/S0014-5793(00)02208-0View ArticleGoogle Scholar
- Ferrari G, Terushkin V, Wolff MJ, Zhang X, Valacca C, Poggio P, Pintucci G, Mignatti P: TGF-beta1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38beta to proapoptotic p38alpha. Mol Cancer Res 2012, 10: 605–614. 10.1158/1541-7786.MCR-11-0507View ArticleGoogle Scholar
- Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM, Reinmuth N: Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 2001, 28: 94–104.View ArticleGoogle Scholar
- Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21: 505–515. 10.1093/carcin/21.3.505View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.